NCT04537936

Brief Summary

The purpose of this study is to adapt a counseling intervention called Meaning Centered Psychotherapy to make it culturally relevant for Latinos. Cancer affects patients and their loved ones. Latinos often experience greater challenges due to the cancer. However, few studies and interventions focus on Latinos. We are interested in understanding what affects Latino patients' quality of life, and how to improve it

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
285

participants targeted

Target at P75+ for not_applicable

Timeline
4mo left

Started Jan 2019

Longer than P75 for not_applicable

Geographic Reach
2 countries

4 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress96%
Jan 2019Aug 2026

Study Start

First participant enrolled

January 1, 2019

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

September 1, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 3, 2020

Completed
6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2026

Last Updated

October 9, 2025

Status Verified

October 1, 2025

Enrollment Period

7.7 years

First QC Date

September 1, 2020

Last Update Submit

October 8, 2025

Conditions

Keywords

Stage III solid tumor cancerStage IV solid tumor cancerStage III cancerStage IV cancerSpanishMemorial Sloan Kettering Cancer Center15-076

Outcome Measures

Primary Outcomes (1)

  • Spiritual Well-Being measured with the FACIT Spiritual Well-Being Scale

    FACIT Spiritual Well-Being Scale is a brief self-report measure designed to assess the nature and extent of individual spiritual well-being. This measure, which generates two sub-scales, one corresponding to Faith (the importance of faith and spirituality) and a second assessing Meaning-Peace (one sense of meaning and purpose in life), has been demonstrated to have strong internal reliability for both the total score as well as each subscale (coefficient alpha equals .87 for the total scale, .88 for the faith factor and .81 for the meaning factor). In additional, strong support for the external validity of this measure has been demonstrated in a several large samples of cancer and AIDS patients and with Spanish speaking populations.

    Change from baseline to post assessment 7-14 weeks after

Secondary Outcomes (3)

  • Depression and Anxiety measured with the Hospital Anxiety and Depression Scale

    Change from baseline to post assessment 7-14 weeks after

  • Hopelessness measured with the Beck Hopelessness Scale

    Change from baseline to post assessment 7-14 weeks after

  • Quality of life measured with the FACIT Spiritual Well-Being Scale

    Change from baseline to post assessment 7-14 weeks after

Study Arms (2)

Meaning Centered Psychotherapy for Latinos (MCP-L)

EXPERIMENTAL
Behavioral: Meaning Centered Psychotherapy for LatinosBehavioral: Functional Assessment of Cancer Therapy - Spiritual Well-Being ScaleBehavioral: Meaning Centered Psychotherapy for Latinos for Waitlist Control PatientsBehavioral: Pre-assessment questionnaire

Control

ACTIVE COMPARATOR
Behavioral: Meaning Centered Psychotherapy for LatinosBehavioral: Functional Assessment of Cancer Therapy - Spiritual Well-Being ScaleBehavioral: Meaning Centered Psychotherapy for Latinos for Waitlist Control PatientsBehavioral: Pre-assessment questionnaire

Interventions

MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span of 7-14 weeks.

Also known as: MCP-L
ControlMeaning Centered Psychotherapy for Latinos (MCP-L)

Determines the degree of spiritual well-being

ControlMeaning Centered Psychotherapy for Latinos (MCP-L)

Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.

ControlMeaning Centered Psychotherapy for Latinos (MCP-L)

Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.

ControlMeaning Centered Psychotherapy for Latinos (MCP-L)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Phase I: Quantitative
  • Diagnosed with stages III or IV solid tumor cancer \*(as per self report for ICCAN patients)
  • Age 18 or older
  • As per self report, Latino/a or Hispanic ethnicity
  • As per self report, fluent in oral Spanish (monolingual) or fluent in oral Spanish and English (bilingual)
  • Phase 2: Qualitative
  • Enrolled in the quantitative phase of study (as seen above)
  • Completes the quantitative phase questionnaire
  • Scores above or below the threshold for the Distress Thermometer (DT≥4 or ≤3)
  • In the judgment of the investigator, willing and able to be interviewed in Spanish only
  • Agrees to be audio- recorded
  • Phase 3: Provider Feedback
  • Professionals working in the mental health field;
  • Have a caseload of five or more Latino cancer patients per month
  • Able to communicate and read in Spanish
  • +14 more criteria

You may not qualify if:

  • Phase 1: Quantitative
  • In the judgment of the treating physician and/or the consenting professional, presence of significant cognitive impairment (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection
  • In the judgment of the consenting professional, significant or major disabling medical or psychiatric condition sufficient to preclude meaningful informed consent, interview, or completion of assessment measures (patients whose psychiatric disorder is well controlled by treatment will be eligible)
  • Phase 2: Qualitative
  • In the judgment of the treating physician and/or the consenting professional, presence of significant cognitive impairment (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection
  • In the judgment of the consenting professional, significant or major disabling medical or psychiatric condition sufficient to preclude meaningful informed consent, interview, or completion of assessment measures (patients whose psychiatric disorder is well controlled by treatment will be eligible)
  • Phase 4: Patient Feedback
  • Diagnosed with a major disabling medical or psychiatric condition
  • Unable to understand the consent procedure
  • Too ill to participate, all as reported by the patient and/or determined by the investigator's judgment.
  • Phase 5: Pilot RCT
  • Diagnosed with a major disabling medical
  • Diagnosed with a major disabling psychiatric condition
  • Unable to understand the consent procedure
  • Too ill to participate, all as reported by the patient and/or determined by the investigator's judgment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

MSK at Ralph Lauren

New York, New York, 10035, United States

RECRUITING

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

RECRUITING

Lincoln Medical and Mental Health Center

The Bronx, New York, 10451, United States

RECRUITING

Ponce Health Sciences University

Ponce, 00732, Puerto Rico

RECRUITING

Related Links

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Rosario Costas-Muniz, PhD

    Memorial Sloan Kettering Cancer Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Rosario Costas-Muniz, PhD

CONTACT

William Breitbart, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 1, 2020

First Posted

September 3, 2020

Study Start

January 1, 2019

Primary Completion (Estimated)

August 31, 2026

Study Completion (Estimated)

August 31, 2026

Last Updated

October 9, 2025

Record last verified: 2025-10

Data Sharing

IPD Sharing
Will share

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Locations